Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC reduced its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 938,944 shares of the company’s stock after selling 41,590 shares during the period. Geneva Capital Management LLC’s holdings in Omnicell were worth $35,332,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of OMCL. Charles Schwab Investment Management Inc. lifted its holdings in shares of Omnicell by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 483,443 shares of the company’s stock worth $18,192,000 after acquiring an additional 32,548 shares during the period. M&T Bank Corp lifted its holdings in shares of Omnicell by 16.0% during the 4th quarter. M&T Bank Corp now owns 9,570 shares of the company’s stock worth $360,000 after acquiring an additional 1,321 shares during the period. Summit Global Investments lifted its holdings in shares of Omnicell by 24.9% during the 4th quarter. Summit Global Investments now owns 20,855 shares of the company’s stock worth $785,000 after acquiring an additional 4,158 shares during the period. Victory Capital Management Inc. grew its position in shares of Omnicell by 465.1% during the fourth quarter. Victory Capital Management Inc. now owns 44,766 shares of the company’s stock worth $1,685,000 after buying an additional 36,844 shares in the last quarter. Finally, Avory & Company LLC grew its position in shares of Omnicell by 25.6% during the fourth quarter. Avory & Company LLC now owns 193,162 shares of the company’s stock worth $7,269,000 after buying an additional 39,386 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on OMCL shares. Wells Fargo & Company decreased their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. Benchmark reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

Omnicell stock traded up $0.29 during midday trading on Thursday, reaching $30.25. 679,330 shares of the stock traded hands, compared to its average volume of 537,458. Omnicell, Inc. has a fifty-two week low of $25.69 and a fifty-two week high of $77.14. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -65.76, a PEG ratio of 237.43 and a beta of 0.77. The firm has a fifty day moving average price of $27.99 and a two-hundred day moving average price of $31.50.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The business had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. On average, equities research analysts forecast that Omnicell, Inc. will post 0.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.